Serum macrophage migration inhibitory factor is an early marker of pancreatic necrosis in acute pancreatitis

Annals of Surgery

Volumn 245, Issue 2, 2007, Pages 282-289

  Rahman, Sakhawat H ^a   Menon, Krishna V ^a   Holmfield, John H M ^b   McMahon, Michael J ^b   Guillou, J Pierre ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLASE; C REACTIVE PROTEIN; CD14 ANTIGEN; CD163 ANTIGEN; MACROPHAGE MIGRATION INHIBITION FACTOR;

ABDOMINAL PAIN; ACUTE PANCREATITIS; ADOLESCENT; ADULT; AGED; AMYLASE BLOOD LEVEL; APACHE; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE MARKER; DISEASE SEVERITY; EARLY DIAGNOSIS; FEMALE; HUMAN; MACROPHAGE MIGRATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE ORGAN FAILURE; MULTIVARIATE ANALYSIS; PANCREAS NECROSIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; SEPSIS;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; ANTIGENS, CD14; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; BIOLOGICAL MARKERS; ENGLAND; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MALE; MIDDLE AGED; PAIN MEASUREMENT; PANCREATITIS, ACUTE NECROTIZING; PROGNOSIS; RECEPTORS, CELL SURFACE; RECEPTORS, SCAVENGER; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TIME FACTORS;

EID: 33846410279     PISSN: 00034932     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.sla.0000245471.33987.4b     Document Type: Article

References (60)

1. McKay CJ, Imrie CW. The continuing challenge of early mortality in acute pancreatitis. Br J Surg. 2004;91:1243-1244.
2. Mann DV, Hershman MJ, Hittinger R, et al. Multicentre audit of death in acute pancreatitis. Br J Surg. 1994;81:890-893.
3. Renner IG, Savage WT III, et al. Deaths due to acute pancreatitis: a prospective analysis of 405 autopsy cases. Dig Dis Sci. 1985;30:1005.
4. Buggy BP, Nostrant TT. Lethal pancreatitis. Am J Gastroenterol. 1983; 78:810-814.
5. Beger HG, Bittner R, Block S, et al. Bacterial contamination of pancreatic necrosis: a prospective clinical study. Gastroenterology. 1986;91: 433-438.
6. Gerzof SA, Banks PA, Robbins AH, et al. Early diagnosis of pancreatic infection by computed tomography-guided aspiration. Gastroenterology. 1987;93:1315-1320.
7. Bassi C, Falconi M, Girelli R, et al. Microbiological findings in severe pancreatitis. Surg Res Commun. 1989;5:1-4.
8. Bradley EL III. A clinically based classification system for acute pancreatitis. Arch Surg. 1993;128:586-590.
9. Isenmann R, Rau B, Beger HG. Bacterial infection and extent of necrosis in severe acute pancreatitis are determinants of organ failure in patients with acute necrotizing pancreatitis. Br J Surg. 1999;86:1020-1024.
10. UK Working Party on Acute Pancreatitis. UK guidelines for the management of acute pancreatitis. Gut 2005;54:iii1-iii9.
11. Ranson JHC, Rifkind KM, Roses DF, et al. Prognostic signs and the role of operative management in acute pancreatitis. Surg Gynecol Obstet. 1974;139:69-81.
12. Karimgani I, Porter K, Langevin R, et al. Prognostic factors in sterile pancreatic necrosis. Gastroenterology. 1992;103:1636-1640.
13. Wilson C, Heads A, Shenkin A, et al. C-reactive protein, antiproteases and complement factors as objective markers of severity in acute pancreatitis. Br J Surg. 1989;76:177-181.
14. Mayer JM, Rau B, Siech M, et al. Local and systemic zymogen activation in human acute pancreatitis. Digestion. 2000;62:164-170.
15. Appelros S, Petersson U, Toh S, et al. Activation peptide of carboxypeptidase B and anionic trypsinogen as early predictors of the severity of acute pancreatitis. Br J Surg. 2001;88:216-221.
16. Borgstrom A, Lasson A. Trypsin-alpha 1-protease inhibitor complexes in serum and clinical course of acute pancreatitis. Scand J Gastroenterol. 1984;19:1119-1122.
17. Gudgeon AM, Heath D, Hurley P, et al. Trypsinogen activation peptide assay in the early prediction of severity of acute pancreatitis. Lancet. 1990;335:4-8.
18. Hedstrom J, Sainio V, Kemppainen E, et al. Serum complex of trypsin 2 and alpha 1 anti-trypsin as diagnostic and prognostic marker of acute pancreatitis: clinical study in consecutive patients. BMJ. 1996;313:333-337.
19. Hedstrom J, Haglund C, Leinonen J, et al. Trypsinogen-1, -2 and tumour-associated trypsin-inhibitor in bile and biliary tract tissues from patients with biliary tract diseases and pancreatic carcinomas. Scand J Clin Lab Invest. 2001;61:111-118.
20. Sainio V, Puolakkainen P, Kemppainen E, et al. Serum trypsinogen-2 in the prediction of outcome in acute necrotizing pancreatitis. Scand J Gastroenterol. 1996;31:818-824.
21. Larvin M, McMahon MJ. Apache-II score for assessment and monitoring of acute pancreatitis. Lancet. 1989;22:201-205.
22. Rahman SH, Salter G, Holmfield JHM, et al. Soluble CD14 receptor expression and monocyte heterogeneity but not the C-260T CD14 genotype is associated with severe acute pancreatitis. Crit Care Med. 2004;32:2457-2463.
23. Kristiansen M, Graversen J, Jacobsen J, et al. Identification of the hemoglobin scavenger receptor. Nature. 2001;409:198-201.
24. Zwadlo G, Voegeli R, Osthoff KS, et al. A mAb to a novel differentiation antigen on human macrophages associated with the down-regulatory phase of the inflammatory process. Exp Cell Biol. 1987;55:295-304.
25. Møller HJ, Peterslund NA, Graversen JH, et al. Identification of the hemoglobin scavenger receptor/CD163 as a natural soluble protein in plasma. Blood. 2002;99:378-380.
26. Bloom BR, Bennett B. Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. Science. 1966;153:80-82.
27. Calandra T, Bernhagen J, Metz CN, et al. MIF as a glucocorticoid-induced modulator of cytokine production. Nature. 1995;377:68-71.
28. Sakai Y, Masamune A, Satoh A, et al. Macrophage migration inhibitory factor is a critical mediator of severe acute pancreatitis. Gastroenterology. 2003;124:725-736.
29. Fenton-Lee D, Imrie CW. Pancreatic necrosis: assessment of outcome related to quality of life and cost of management. Br J Surg. 1993;80: 1579-1582.
30. Trinto A, Lloyd DA, Kang JY, et al. Acute and chronic pancreatitis-diseases on the rise: a study of hospital admissions in England 1989/ 90-1999/2000. Aliment Pharmacol Ther. 2002;16:2097-2105.
31. McKay CJ, Buter A. Natural history of organ failure in acute pancreatitis. Pancreatology. 2003;3:111-114.
32. Nishino T, Bernhagen J, Shiiki H, et al. Localization of macrophage-migration inhibitory factor (MIF) to secretory granules within the corticotropic and thyrotropic cells of the pituitary-gland. Mol Med. 1995;1:781-788.
33. Bacher M, Meinhardt A, Lan HY, et al. Migration inhibitory factor expression in experimentally induced endotoxemia. Am J Pathol. 1997; 150:235-246.
34. Donnelly SC, Haslett C, Reid PT, et al. Regulatory role for macrophage migration inhibitory factor in acute respiratory distress syndrome. Nat Med. 1997;3:320-323.
35. Chesney J, Metz C, Bacher M, et al. An essential role for macrophage migration inhibitory factor (MIF) in angiogenesis and the growth of a murine lymphoma. Mol Med. 1999;5:181-191.
36. Shimizu T, Abe R, Nakamura H, et al. High expression of macrophage migration inhibitory factor in human melanoma cells and its role in tumor cell growth and angiogenesis. Biochem Biophys Res Commun. 1999;264:751-758.
37. Calandra T, Spiegel LA, Metz CN, et al. Macrophage migration inhibitory factor is a critical mediator of the activation of immune cells by exotoxins of gram-positive bacteria. Proc Natl Acad Sci USA. 1998;95: 11383-11388.
38. Calandra T, Bernhagen J, Mitchell RA, et al. The macrophage is an important and previously unrecognized source of macrophage-migration inhibitory factor. J Exp Med. 1994;179:1895-1902.
39. Bacher M, Metz CN, Calandra T, et al. An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. Proc Natl Acad Sci USA. 1996;93:7849-7854.
40. Benigni F, Atsumi T, Calandra T, et al. The proinflammatory mediator macrophage migration inhibitory factor induces glucose catabolism in muscle. J Clin Invest. 2000;106:1291-1300.
41. Bernhagen J, Calandra T, Mitchell RA, et al. Purification and characterization of the cytokine macrophage-migration inhibitory factor (MIF). FASEB J. 1994;8:A1417.
42. Onodera S, Kaneda K, Mizue Y, et al. Macrophage migration inhibitory factor upregulates expression of matrix metalloproteinases in synovial fibroblasts of rheumatoid arthritis. J Biol Chem. 2000;275:444-450.
43. Mitchell RA, Metz CN, Peng T, et al. Sustained mitogen-activated protein kinase (MAPK) and cytoplasmic phospholipase A2 activation by macrophage migration inhibitory factor (MIF): regulatory role in cell proliferation and glucocorticoid action. J Biol Chem. 1999;274:18100-18106.
44. Bucala R. MIF rediscovered: cytokine, pituitary hormone, and glucocorticoid-induced regulator of the immune response. FASEB J. 1996;10: 1607-1613.
45. Calandra T, Echtenacher B, Roy DL, et al. Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat Med. 2000;6:164-170.
46. Echtenacher B, Falk W, Mannel DN, et al. Requirement of endogenous tumor necrosis factor/cachectin for recovery from experimental peritonitis. J Immunol. 1990;145:3762-3766.
47. Beishuizen A, Thijs LG, Haanen C, et al. Macrophage migration inhibitory factor and hypothalamo-pituitary-adrenal function during critical illness. J Clin Endocrinol Metab. 2001;86:2811-2816.
48. Joshi PC, Poole GV, Sachdev V, et al. Trauma patients with positive cultures have higher levels of circulating macrophage migration inhibitory factor (MIF). Res Commun Mol Pathol Pharmacol. 2000;107:13-20.
49. Rahman SH, Ammori BJ, Holmfield JHM, et al. Intestinal hypoperfusion contributes to gut barrier failure in severe acute pancreatitis. J Gastrointest Surg. 2003;7:26-36.
50. Bassi C, Larvin M, Villatoro E. Antibiotic therapy for prophylaxis against infection of pancreatic necrosis in acute pancreatitis. Cochrane Database Syst Rev. 2003;(4):CD002941.
51. Isenmann R, Schwarz M, Rau B, et al. Characteristics of infection with candida species in patients with necrotizing pancreatitis. World J Surg. 2002;25:372-376.
52. de Beaux AC, Goldie AS, Ross JA, et al. Serum concentrations of inflammatory mediators related to organ failure in patients with acute pancreatitis. Br J Surg. 1996;83:349-353.
53. Pezzilli R, Billi P, Miniero R, et al. Serum interleukin-6, interleukin-8, and beta2-microglobulin in early assessment of severity of acute pancreatitis: comparison with C-reactive protein. Dig Dis Sci. 1995;40: 2341-2348.
54. Froidevaux C, Roger T, Martin C, et al. Macrophage migration inhibitory factor and innate immune responses to bacterial infections. Crit Care Med. 2001;297(suppl):13-15.
55. Denhardt DT. Signal-transducing protein phosphorylation cascades mediated by Ras/Rho proteins in the mammalian cell: the potential for multiplex signalling. Biochem J. 1996;318:729-747.
56. Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med. 1997;336:1066-1071.
57. De Bosscher K, Vanden Berghe W, Vermeulen L, et al. Glucocorticoids repress NFkappaB-driven genes by disturbing the interaction of p65 with the basal transcription machinery, irrespective of coactivator levels in the cell. Proc Natl Acad Sci USA. 2000;97:3919-3924.
58. Scheinman RI, Cogswell PC, Lofquist AK, et al. Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science. 1995;270:283-286.
59. Auphan N, DiDonato JA, Rosette C, et al. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science. 1995;270:286-290.
60. Hudson JD, Shoaibi MA, Maestro R, et al. A proinflammatory cytokine inhibits p53 tumor suppressor activity. J Exp Med. 1999;190:1375-1382.